Replimune Group, Inc. (REPL)
| Market Cap | 993.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -146.73M |
| Shares Out | 54.77M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 403,029 |
| Open | 19.79 |
| Previous Close | 19.98 |
| Day's Range | 19.61 - 20.4 |
| 52-Week Range | 13.05 - 30.89 |
| Beta | 1.86 |
| Analysts | Buy |
| Price Target | 45.70 (+124.9%) |
| Earnings Date | Nov 3, 2022 |
About REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 45.7, which is an increase of 124.90% from the latest price.
News
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu...
Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
WOBURN, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu...
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expe...
3 Lost Formula Stocks to Consider for July
Following a stronger-than-expected jobs report for June, U.S. market indexes rose on Friday as investors anticipate the Federal Reserve will continue with its aggressive interest rate hikes as it attemp...
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
WOBURN, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu...
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo® (nivolumab), and trial-in-progress updates across the RP1, R...
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Onc...
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-...
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu...
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
Data expected to be presented at an investor event in March 2022:
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immun...
Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immu...
Replimune Appoints Christy Oliger to its Board of Directors
WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy pla...
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
Replimune to Present at the William Blair Biotech Focus Conference 2021
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today anno...
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expan...
High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination w...
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
Replimune to Host Virtual Investor Event on June 3, 2021
Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American...
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2
3 Biotech Stocks That Could Double In 12 Months
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...